Next Article in Journal
Extracellular Vesicles in Chronic Obstructive Pulmonary Disease
Next Article in Special Issue
Developmental Origins of Chronic Kidney Disease: Should We Focus on Early Life?
Previous Article in Journal
miR-92a-3p Exerts Various Effects in Glioma and Glioma Stem-Like Cells Specifically Targeting CDH1/β-Catenin and Notch-1/Akt Signaling Pathways
Article Menu
Issue 11 (November) cover image

Export Article

Open AccessArticle
Int. J. Mol. Sci. 2016, 17(11), 1800; doi:10.3390/ijms17111800

Urinary Angiotensinogen Could Be a Prognostic Marker of the Renoprotection of Olmesartan in Metabolic Syndrome Patients

1
Department of Pharmacology, Kagawa University School of Medicine, Kagawa 761-0793, Japan
2
Departments of Pharmacology and of Nephrology, School of Medicine, International University of Health and Welfare, Tokyo 107-0062, Japan
3
Departments of Physiology and of Medicine, Tulane University Health Sciences Center, New Orleans, LA 70112, USA
4
Department of Medicine, Kagawa University School of Medicine, Kagawa 761-0793, Japan
5
The Second Department of Internal Medicine, Toyama University School of Medicine, Toyama 930-0194, Japan
6
The Second Department of Internal Medicine, Kansai Medical University, Osaka 573-1010, Japan
*
Author to whom correspondence should be addressed.
Academic Editor: Alan Parrish
Received: 22 June 2016 / Revised: 16 August 2016 / Accepted: 19 August 2016 / Published: 27 October 2016
(This article belongs to the Special Issue Advances in Chronic Kidney Disease 2017)
View Full-Text   |   Download PDF [1841 KB, uploaded 27 October 2016]   |  

Abstract

This study was performed to demonstrate urinary angiotensinogen as a potential prognostic marker of the albuminuria reduction effects of olmesartan in patients with metabolic syndrome. In 24 patients (eight women, 57.88 ± 2.00 years), 5–40 mg/day of olmesartan were given. Urinary concentrations of albumin and angiotensinogen (normalized by urinary concentrations of creatinine) and plasma renin activity were measured before and after the 12- and 24-week marks of olmesartan treatment. Olmesartan treatment increased plasma renin activity and decreased urinary albumin and urinary angiotensinogen significantly (p < 0.05). Based on the % change in urinary albumin, patients were divided into two groups, responders (<−50%) and non-responders (≥−50%), and a logistic analysis of urinary angiotensinogen before treatment showed the area under the curve as 0.694. When the cutoff value of urinary angiotensinogen before the treatment of 13.9 µg/g Cr was used, the maximum Youden index (0.500, specificity: 11/12 = 91.7% and sensitivity: 7/12 = 58.3%) was obtained. When all patients were re-divided into two groups, those with higher values of urinary angiotensinogen before the treatment (Group H, n = 16) and those with lower values, Group H showed significantly decreased urinary albumin (p < 0.05). Therefore, urinary angiotensinogen could be a prognostic marker of the albuminuria reduction effects of olmesartan in patients with metabolic syndrome. View Full-Text
Keywords: urinary angiotensinogen; metabolic syndrome; angiotensin receptor blocker; renin-angiotensin system; prognostic marker of albuminuria reduction effects urinary angiotensinogen; metabolic syndrome; angiotensin receptor blocker; renin-angiotensin system; prognostic marker of albuminuria reduction effects
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Supplementary material

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Mizushige, T.; Kobori, H.; Hitomi, H.; Nishijima, Y.; Tomoda, F.; Morimoto, S.; Kohno, M.; Nishiyama, A. Urinary Angiotensinogen Could Be a Prognostic Marker of the Renoprotection of Olmesartan in Metabolic Syndrome Patients. Int. J. Mol. Sci. 2016, 17, 1800.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top